Article
HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.
JCI insight - 30 Jan 2020
Easterhoff David, Pollara Justin, Luo Kan, Janus Benjamin, Gohain Neelakshi, Williams LaTonya D, Tay Matthew Zirui, Monroe Anthony, Peachman Kristina, Choe Misook, Min Susie, Lusso Paolo, Zhang Peng, Go Eden P, Desaire Heather, Bonsignori Mattia, Hwang Kwan-Ki, Beck Charles, Kakalis Matina, O'Connell Robert J, Vasan Sandhya, Kim Jerome H, Michael Nelson L, Excler Jean-Louis, Robb Merlin L, Rerks-Ngarm Supachai, Kaewkungwal Jaranit, Pitisuttithum Punnee, Nitayaphan Sorachai, Sinangil Faruk, Tartaglia James, Phogat Sanjay, Wiehe Kevin, Saunders Kevin O, Montefiori David C, Tomaras Georgia D, Moody M Anthony, Arthos James, Rao Mangala, Joyce M Gordon, Ofek Gilad, Ferrari Guido, Haynes Barton F
Abstract excerpt
In the RV144 HIV-1 phase III trial, vaccine efficacy directly correlated with the magnitude of the variable region 2-specific (V2-specific) IgG antibody response, and in the presence of low plasma IgA levels, with the magnitude of plasma antibody-dependent cellular cytotoxicity. Reenrollment of RV144 vaccinees in the RV305 trial offered the opportunity to define the function, maturation, and persistence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.